Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Parkinson Disease, 10 Years After Its Genetic Revolution: Multiple Clues to a Complex Disorder
Neurol 69:2093-2104, Klein,C. &Schlossmacher,M.G., 2007
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
A 60-Year-Old Man with Parkinson's Disease
JAMA 275:716-722, Olanow,C.W., 1996
Advances in Neurology
NEJM 326:1608-1616, 1671-16761992., Gilman,S., 1992
Gait Analysis in Neurologic Disorders, Methodology, Applications and Clinical Considerations
Neurol 105:e214154, Ali,F.,et al, 2025
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Tremor
JAMA 311:948-954, Elias, W.J. & Shah, B.B., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
A Multidisciplinary Study of Patients with Early-Onset PD with and Without Parkin Mutations
Neurol 72:110-116,106, Lohmann,E.,et al, 2009
Functional Imaging in Parkinson Disease
Neurol 70:1478-1488, Nandhagopal,R.,et al, 2008
Invited Article: Nervous System Pathology in Sporadic Parkinson Disease
Neurol 70:1916-1925, Braak,H. & Del Tredici,K., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Deep Brain Stimulation
Neurologist 13:237-252, Kem,DS. &Kumar,R., 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006